AstraZeneca PLC (AZN) Debt to Assets Ratio: 0.26%
The debt to assets ratio for AstraZeneca PLC (AZN) is 0.26% as of Friday, June 12, 2026.
AZN Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.26%
AZN Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 0.26% |
| Merck & Co., Inc. (MRK) | $298.29B | 0.37% |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 0.25% |
| Amgen Inc. (AMGN) | $191.09B | 0.60% |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 0.37% |
| AbbVie Inc. (ABBV) | $397.12B | 0.52% |
| Gilead Sciences, Inc. (GILD) | $156.28B | 0.42% |
| Abbott Laboratories (ABT) | $156.15B | 0.17% |
| Pfizer Inc. (PFE) | $149.18B | 0.32% |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 0.01% |
Leverage Ratios Comparison
Debt/Assets
0.3%
Debt/Equity
0.61
Current Ratio
0.94
Interest Coverage
8.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
AstraZeneca PLC Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Debt to Assets Ratio FAQ
- What is the debt to assets ratio for AstraZeneca PLC (AZN)?
- The debt to assets ratio for AZN stock is 0.26%.
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot